Last reviewed · How we verify
Aromatase inhibitor and GnRH analog
Aromatase inhibitor and GnRH analog is a Small molecule drug developed by Centre for Endocrinology and Reproductive Medicine, Italy. It is currently FDA-approved. Also known as: experimental group.
At a glance
| Generic name | Aromatase inhibitor and GnRH analog |
|---|---|
| Also known as | experimental group |
| Sponsor | Centre for Endocrinology and Reproductive Medicine, Italy |
| Modality | Small molecule |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- Evaluating the Addition of Adjuvant Chemotherapy to Ovarian Function Suppression Plus Endocrine Therapy in Premenopausal Patients With pN0-1, ER-Positive/HER2-Negative Breast Cancer and an Oncotype Recurrence Score Less Than or Equal to 25 (PHASE3)
- TRADE: Dose Escalation Tolerability of Abemaciclib in HR+ HER2- Early Stage Breast Cancer (PHASE2)
- Endocrine Therapy With Abemaciclib or Chemotherapy as Initial Metastatic Treatment in ER+/HER2- Breast Cancer (PHASE3)
- Three Drug Combination Therapy Versus Conventional Treatment of Children With Congenital Adrenal Hyperplasia (PHASE3)
- Gonadotropin-releasing Hormone Agonist (GnRHa) Plus Letrozole In Young Women With Early Endometrial Cancer (PHASE2)
- Palbociclib for HR Positive / HER2-negative Isolated Locoregional Recurrence of Breast Cancer (PHASE3)
- Neoadjuvant Endocrine Therapy +/- the PI3K Inhibitor Inavolisib in HER2+, HR+, PIK3CA Mutant Early Breast Cancer (PHASE2)
- Locoregional Treatment and Palbociclib in de Novo, Treatment Naive, Stage IV ER+, HER2- Breast Cancer Patients (NA)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Aromatase inhibitor and GnRH analog CI brief — competitive landscape report
- Aromatase inhibitor and GnRH analog updates RSS · CI watch RSS
- Centre for Endocrinology and Reproductive Medicine, Italy portfolio CI
Frequently asked questions about Aromatase inhibitor and GnRH analog
What is Aromatase inhibitor and GnRH analog?
Aromatase inhibitor and GnRH analog is a Small molecule drug developed by Centre for Endocrinology and Reproductive Medicine, Italy.
Who makes Aromatase inhibitor and GnRH analog?
Aromatase inhibitor and GnRH analog is developed and marketed by Centre for Endocrinology and Reproductive Medicine, Italy (see full Centre for Endocrinology and Reproductive Medicine, Italy pipeline at /company/centre-for-endocrinology-and-reproductive-medicine-italy).
Is Aromatase inhibitor and GnRH analog also known as anything else?
Aromatase inhibitor and GnRH analog is also known as experimental group.
What development phase is Aromatase inhibitor and GnRH analog in?
Aromatase inhibitor and GnRH analog is FDA-approved (marketed).
Related
- Manufacturer: Centre for Endocrinology and Reproductive Medicine, Italy — full pipeline
- Also known as: experimental group
- Compare: Aromatase inhibitor and GnRH analog vs similar drugs
- Pricing: Aromatase inhibitor and GnRH analog cost, discount & access